WÄDENSWIL, Switzerland--(BUSINESS WIRE)--Numab AG, a company focused on the discovery and development of innovative antibody-based therapeutics, announced today that it has reacquired the rights to ND003, a bispecific anti-IL5RxCD3 antibody fragment for the targeted lysis of eosinophils in severe asthma, from Sucampo AG, a subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP).
Help employers find you! Check out all the jobs and post your resume.
